1. Home
  2. FIHL vs LQDA Comparison

FIHL vs LQDA Comparison

Compare FIHL & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FIHL
  • LQDA
  • Stock Information
  • Founded
  • FIHL 2014
  • LQDA 2004
  • Country
  • FIHL Bermuda
  • LQDA United States
  • Employees
  • FIHL N/A
  • LQDA N/A
  • Industry
  • FIHL
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • FIHL
  • LQDA Health Care
  • Exchange
  • FIHL Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • FIHL 1.6B
  • LQDA 1.7B
  • IPO Year
  • FIHL 2023
  • LQDA 2018
  • Fundamental
  • Price
  • FIHL $17.48
  • LQDA $27.28
  • Analyst Decision
  • FIHL Hold
  • LQDA Strong Buy
  • Analyst Count
  • FIHL 6
  • LQDA 10
  • Target Price
  • FIHL $20.67
  • LQDA $31.40
  • AVG Volume (30 Days)
  • FIHL 708.7K
  • LQDA 3.1M
  • Earning Date
  • FIHL 08-13-2025
  • LQDA 08-12-2025
  • Dividend Yield
  • FIHL 3.43%
  • LQDA N/A
  • EPS Growth
  • FIHL N/A
  • LQDA N/A
  • EPS
  • FIHL N/A
  • LQDA N/A
  • Revenue
  • FIHL $2,607,600,000.00
  • LQDA $19,322,000.00
  • Revenue This Year
  • FIHL $21.24
  • LQDA $362.31
  • Revenue Next Year
  • FIHL $4.94
  • LQDA $418.29
  • P/E Ratio
  • FIHL N/A
  • LQDA N/A
  • Revenue Growth
  • FIHL 21.21
  • LQDA 30.20
  • 52 Week Low
  • FIHL $14.17
  • LQDA $8.75
  • 52 Week High
  • FIHL $21.32
  • LQDA $28.82
  • Technical
  • Relative Strength Index (RSI)
  • FIHL 60.06
  • LQDA 70.92
  • Support Level
  • FIHL $16.76
  • LQDA $27.23
  • Resistance Level
  • FIHL $17.91
  • LQDA $28.82
  • Average True Range (ATR)
  • FIHL 0.53
  • LQDA 1.42
  • MACD
  • FIHL 0.02
  • LQDA -0.08
  • Stochastic Oscillator
  • FIHL 78.43
  • LQDA 80.44

About FIHL Fidelis Insurance Holdings Limited

Fidelis Insurance Holdings Ltd is a specialty insurer that leverages strategic partnerships to offer tailored insurance solutions. The company classifies its business into two segments, Insurance and Reinsurance. A majority of its revenue is generated from the Insurance segment, which comprises a portfolio of property, marine, aviation and aerospace, political risk, violence and terror, energy, cyber, and other insurance risks. The Reinsurance segment consists of an actively managed property reinsurance book, providing reinsurance and a limited amount of retrocession coverage across the world on a proportional or excess-of-loss basis. Geographically, the company derives its key revenue from the United Kingdom, followed by Bermuda and the Republic of Ireland.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: